- Home
- WGRX vs VOR Comparison
WGRX vs VOR Comparison
Compare WGRX & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- VOR
- Stock Information
- Founded
- WGRX 2022
- VOR 2015
- Country
- WGRX United States
- VOR United States
- Employees
- WGRX N/A
- VOR N/A
- Industry
- WGRX Other Pharmaceuticals
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- VOR Health Care
- Exchange
- WGRX Nasdaq
- VOR Nasdaq
- Market Cap
- WGRX 140.2M
- VOR 134.8M
- IPO Year
- WGRX 2025
- VOR 2021
- Fundamental
- Price
- WGRX $3.29
- VOR $0.65
- Analyst Decision
- WGRX
- VOR Strong Buy
- Analyst Count
- WGRX 0
- VOR 7
- Target Price
- WGRX N/A
- VOR $9.43
- AVG Volume (30 Days)
- WGRX 219.8K
- VOR 235.2K
- Earning Date
- WGRX 01-01-0001
- VOR 05-08-2025
- Dividend Yield
- WGRX N/A
- VOR N/A
- EPS Growth
- WGRX N/A
- VOR N/A
- EPS
- WGRX N/A
- VOR N/A
- Revenue
- WGRX $18,128,831.00
- VOR N/A
- Revenue This Year
- WGRX N/A
- VOR N/A
- Revenue Next Year
- WGRX N/A
- VOR N/A
- P/E Ratio
- WGRX N/A
- VOR N/A
- Revenue Growth
- WGRX N/A
- VOR N/A
- 52 Week Low
- WGRX $2.32
- VOR $0.49
- 52 Week High
- WGRX $5.69
- VOR $1.95
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- VOR 38.81
- Support Level
- WGRX N/A
- VOR $0.49
- Resistance Level
- WGRX N/A
- VOR $0.75
- Average True Range (ATR)
- WGRX 0.00
- VOR 0.07
- MACD
- WGRX 0.00
- VOR 0.02
- Stochastic Oscillator
- WGRX 0.00
- VOR 59.04
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.